Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies

Cancer Letters

Volumn 344, Issue 1, 2014, Pages 13-19

  Zhou, Qianjun ^a   Facciponte, John ^b   Jin, Min ^c   Shen, Qiang ^d   Lin, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY AT BUFFALO   (United States)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Humanized mice; Immunodeficient mice; Preclinical model; Tumor model; Xenograft

Indexed keywords

CHEMOKINE RECEPTOR CCR4; I KAPPA B KINASE INHIBITOR; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR GAMMA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KM2760; PACLITAXEL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

CANCER MODEL; CANCER PROGNOSIS; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CUTANEOUS T CELL LYMPHOMA; DOSE RESPONSE; DRUG MEGADOSE; GENE EXPRESSION REGULATION; HEPATOBLASTOMA; HUMAN; IL2RG GENE; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NOD SCID GAMMA MOUSE; NONHUMAN; OVARY CANCER; PERSONALIZED MEDICINE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SHORT SURVEY; STRAIN DIFFERENCE; T CELL LEUKEMIA; TUMOR PROMOTION; TUMOR XENOGRAFT;

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INDIVIDUALIZED MEDICINE; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893663882     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.015     Document Type: Review

References (70)

1. Rygaard J., Povlsen C.O. Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathologica et Microbiologica Scandinavica 1969, 77:758-760.
2. Mosier D.E., Gulizia R.J., Baird S.M., Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988, 335:256-259.
3. Lapidot T., Pflumio F., Doedens M., Murdoch B., Williams D.E., Dick J.E. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 1992, 255:1137-1141.
4. Hesselton R.M., Greiner D.L., Mordes J.P., Rajan T.V., Sullivan J.L., Shultz L.D. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J. Infect. Dis. 1995, 172:974-982.
5. Pflumio F., Izac B., Katz A., Shultz L.D., Vainchenker W., Coulombel L. Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. Blood 1996, 88:3731-3740.
6. Shultz L.D., Schweitzer P.A., Christianson S.W., Gott B., Schweitzer I.B., Tennent B., McKenna S., Mobraaten L., Rajan T.V., Greiner D.L., et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 1995, 154:180-191.
7. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., Heike T., Nakahata T. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
8. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., Kotb M., Gillies S.D., King M., Mangada J., Greiner D.L., Handgretinger R. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174:6477-6489.
9. Cao X., Shores E.W., Hu-Li J., Anver M.R., Kelsall B.L., Russell S.M., Drago J., Noguchi M., Grinberg A., Bloom E.T., et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995, 2:223-238.
10. Ohbo K., Suda T., Hashiyama M., Mantani A., Ikebe M., Miyakawa K., Moriyama M., Nakamura M., Katsuki M., Takahashi K., Yamamura K., Sugamura K. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 1996, 87:956-967.
11. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
12. Gimeno R., Weijer K., Voordouw A., Uittenbogaart C.H., Legrand N., Alves N.L., Wijnands E., Blom B., Spits H. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells. Blood 2004, 104:3886-3893.
13. DiSanto J.P., Muller W., Guy-Grand D., Fischer A., Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. USA 1995, 92:377-381.
14. Kirchgessner C.U., Patil C.K., Evans J.W., Cuomo C.A., Fried L.M., Carter T., Oettinger M.A., Brown J.M. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995, 267:1178-1183.
15. Ito R., Katano I., Ida-Tanaka M., Kamisako T., Kawai K., Suemizu H., Aiso S., Ito M. Efficient xenoengraftment in severe immunodeficient NOD/Shi-scid IL2rgammanull mice is attributed to a lack of CD11c+B220+CD122+ cells. J. Immunol. 2012, 189:4313-4320.
16. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
17. Strowig T., Rongvaux A., Rathinam C., Takizawa H., Borsotti C., Philbrick W., Eynon E.E., Manz M.G., Flavell R.A. Transgenic expression of human signal regulatory protein alpha in Rag2-/-gamma(c)-/- mice improves engraftment of human hematopoietic cells in humanized mice. Proc. Natl. Acad. Sci. USA 2011, 108:13218-13223.
18. Carreno B.M., Garbow J.R., Kolar G.R., Jackson E.N., Engelbach J.A., Becker-Hapak M., Carayannopoulos L.N., Piwnica-Worms D., Linette G.P. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases. Clin. Cancer Res. 2009, 15:3277-3286.
19. Agliano A., Martin-Padura I., Mancuso P., Marighetti P., Rabascio C., Pruneri G., Shultz L.D., Bertolini F. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int. J. Cancer. J. Int. du Cancer 2008, 123:2222-2227.
20. Christianson S.W., Greiner D.L., Hesselton R.A., Leif J.H., Wagar E.J., Schweitzer I.B., Rajan T.V., Gott B., Roopenian D.C., Shultz L.D. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J. Immunol. 1997, 158:3578-3586.
21. Harui A., Kiertscher S.M., Roth M.D. Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation. J. Neuroimmune Pharmacol. 2011, 6:148-157.
22. Seitz G., Pfeiffer M., Fuchs J., Warmann S.W., Leuschner I., Vokuhl C., Lang P., Handgretinger R., Armeanu-Ebinger S. Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol. Rep. 2010, 24:1067-1072.
23. Shultz L.D., Banuelos S., Lyons B., Samuels R., Burzenski L., Gott B., Lang P., Leif J., Appel M., Rossini A., Greiner D.L. NOD/LtSz-Rag1nullPfpnull mice: a new model system with increased levels of human peripheral leukocyte and hematopoietic stem-cell engraftment. Transplantation 2003, 76:1036-1042.
24. McDermott S.P., Eppert K., Lechman E.R., Doedens M., Dick J.E. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 2010, 116:193-200.
25. Bankert R.B., Balu-Iyer S.V., Odunsi K., Shultz L.D., Kelleher R.J., Barnas J.L., Simpson-Abelson M., Parsons R., Yokota S.J. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PloS one 2011, 6:e24420.
26. Zadeh-Khorasani M., Nolte T., Mueller T.D., Pechlivanis M., Rueff F., Wollenberg A., Fricker G., Wolf E., Siebeck M., Gropp R. NOD-scid IL2R gammanull mice engrafted with human peripheral blood mononuclear cells as a model to test therapeutics targeting human signaling pathways. J. Trans. Med. 2013, 11:4.
27. Talmadge J.E., Meyers K.M., Prieur D.J., Starkey J.R. Role of NK cells in tumour growth and metastasis in beige mice. Nature 1980, 284:622-624.
28. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
29. Suemizu H., Monnai M., Ohnishi Y., Ito M., Tamaoki N., Nakamura M. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int. J. Oncol. 2007, 31:741-751.
30. Simpson-Abelson M.R., Sonnenberg G.F., Takita H., Yokota S.J., Conway T.F., Kelleher R.J., Shultz L.D., Barcos M., Bankert R.B. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J. Immunol. 2008, 180:7009-7018.
31. Wege A.K., Ernst W., Eckl J., Frankenberger B., Vollmann-Zwerenz A., Mannel D.N., Ortmann O., Kroemer A., Brockhoff G. Humanized tumor mice-a new model to study and manipulate the immune response in advanced cancer therapy. Int. J. Cancer. J. Int. du Cancer 2011.
32. Sartelet H., Durrieu L., Fontaine F., Nyalendo C., Haddad E. Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. In Vivo 2012, 26:19-29.
33. Dewan M.Z., Watanabe M., Ahmed S., Terashima K., Horiuchi S., Sata T., Honda M., Ito M., Watanabe T., Horie R., Yamamoto N. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. Cancer Sci. 2005, 96:466-473.
34. Fridman R., Kibbey M.C., Royce L.S., Zain M., Sweeney M., Jicha D.L., Yannelli J.R., Martin G.R., Kleinman H.K. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J. Natl. Cancer Inst. 1991, 83:769-774.
35. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
36. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
37. Miyakawa Y., Ohnishi Y., Tomisawa M., Monnai M., Kohmura K., Ueyama Y., Ito M., Ikeda Y., Kizaki M., Nakamura M. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem. Biophys. Res. Commun. 2004, 313:258-262.
38. Bertolini F., Shaked Y., Mancuso P., Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 2006, 6:835-845.
39. Woiterski J., Ebinger M., Witte K.E., Goecke B., Heininger V., Philippek M., Bonin M., Schrauder A., Rottgers S., Herr W., Lang P., Handgretinger R., Hartwig U.F., Andre M.C. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcgammanull mice reflects individual leukemogenecity and highly correlates with clinical outcome. Int. J. Cancer. J. Int. du Cancer 2013, 133:1547-1556.
40. Milsom C.C., Lee C.R., Hackl C., Man S., Kerbel R.S. Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rgamma(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis. PloS one 2013, 8:e71270.
41. Nicholson B.E., Frierson H.F., Conaway M.R., Seraj J.M., Harding M.A., Hampton G.M., Theodorescu D. Profiling the evolution of human metastatic bladder cancer. Cancer Res. 2004, 64:7813-7821.
42. Gildea J.J., Golden W.L., Harding M.A., Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000, 27:252-263.
43. Takenaga K., Nakamura Y., Sakiyama S. Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 1997, 14:331-337.
44. Bjornland K., Winberg J.O., Odegaard O.T., Hovig E., Loennechen T., Aasen A.O., Fodstad O., Maelandsmo G.M. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 1999, 59:4702-4708.
45. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48:589-601.
46. Peterson J.K., Houghton P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 2004, 40:837-844.
47. Kelland L.R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 2004, 40:827-836.
48. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 1996, 2:689-692.
49. Flavell D.J., Warnes S.L., Bryson C.J., Field S.A., Noss A.L., Packham G., Flavell S.U. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. Br. J. Haematol. 2006, 134:157-170.
50. Valdez K.E., Fan F., Smith W., Allred D.C., Medina D., Behbod F. Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J. Pathol. 2011, 225:565-573.
51. Zhao Y., Moon E., Carpenito C., Paulos C.M., Liu X., Brennan A.L., Chew A., Carroll R.G., Scholler J., Levine B.L., Albelda S.M., June C.H. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010, 70:9053-9061.
52. Ito A., Ishida T., Yano H., Inagaki A., Suzuki S., Sato F., Takino H., Mori F., Ri M., Kusumoto S., Komatsu H., Iida S., Inagaki H., Ueda R. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol. Immunother. 2009, 58:1195-1206.
53. Watanabe M., Dewan M.Z., Okamura T., Sasaki M., Itoh K., Higashihara M., Mizoguchi H., Honda M., Sata T., Watanabe T., Yamamoto N., Umezawa K., Horie R. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int. J. Cancer. J. Int. du Cancer 2005, 114:32-38.
54. Snanoudj R., Rouleau M., Bidere N., Carmona S., Baron C., Latinne D., Bazin H., Charpentier B., Senik A. A role for CD2 antibodies (BTI-322 and its humanized form) in the in vivo elimination of human T lymphocytes infiltrating an allogeneic human skin graft in SCID mice: an Fcgamma receptor-related mechanism involving co-injected human NK cells. Transplantation 2004, 78:50-58.
55. Zhang M., Zhang Z., Garmestani K., Goldman C.K., Ravetch J.V., Brechbiel M.W., Carrasquillo J.A., Waldmann T.A. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res. 2004, 64:5825-5829.
56. Shiokawa M., Takahashi T., Murakami A., Kita S., Ito M., Sugamura K., Ishii N. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice. Biochem. Biophys. Res. Commun. 2010, 399:733-737.
57. Barok M., Isola J., Palyi-Krekk Z., Nagy P., Juhasz I., Vereb G., Kauraniemi P., Kapanen A., Tanner M., Szollosi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 2007, 6:2065-2072.
58. Munz C., Dao T., Ferlazzo G., de Cos M.A., Goodman K., Young J.W. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005, 105:266-273.
59. Cany J., van der Waart A.B., Tordoir M., Franssen G.M., Hangalapura B.N., de Vries J., Boerman O., Schaap N., van der Voort R., Spanholtz J., Dolstra H. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PloS one 2013, 8:e64384.
60. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., Najima Y., Takagi S., Aoki Y., Wake A., Taniguchi S., Shultz L.D., Ishikawa F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28:275-280.
61. Harned T.M., Kalous O., Neuwelt A., Loera J., Ji L., Iovine P., Sposto R., Neuwelt E.A., Reynolds C.P. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin. Cancer Res. 2008, 14:533-540.
62. Teitz T., Stanke J.J., Federico S., Bradley C.L., Brennan R., Zhang J., Johnson M.D., Sedlacik J., Inoue M., Zhang Z.M., Frase S., Rehg J.E., Hillenbrand C.M., Finkelstein D., Calabrese C., Dyer M.A., Lahti J.M. Preclinical models for neuroblastoma: establishing a baseline for treatment. PloS one 2011, 6:e19133.
63. Lieber J., Eicher C., Wenz J., Kirchner B., Warmann S.W., Fuchs J., Armeanu-Ebinger S. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer 2011, 11:362.
64. Dewan M.Z., Terashima K., Taruishi M., Hasegawa H., Ito M., Tanaka Y., Mori N., Sata T., Koyanagi Y., Maeda M., Kubuki Y., Okayama A., Fujii M., Yamamoto N. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J. Virol. 2003, 77:5286-5294.
65. Saito M., Iwawaki T., Taya C., Yonekawa H., Noda M., Inui Y., Mekada E., Kimata Y., Tsuru A., Kohno K. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 2001, 19:746-750.
66. Rao M.K., Wilkinson M.F. Tissue-specific and cell type-specific RNA interference in vivo. Nat. Protocols 2006, 1:1494-1501.
67. Yamazaki S., Iwama A., Morita Y., Eto K., Ema H., Nakauchi H. Cytokine signaling, lipid raft clustering, and HSC hibernation. Ann. New York Acad. Sci. 2007, 1106:54-63.
68. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Ann. Rev. Immunol. 1999, 17:255-281.
69. Brehm M.A., Shultz L.D., Greiner D.L. Humanized mouse models to study human diseases. Curr. Opin. Endocrinol., Diabetes, Obesity 2010, 17:120-125.
70. Alcantar-Orozco E.M., Gornall H., Baldan V., Hawkins R.E., Gilham D.E. Potential Limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Human Gene Therapy Methods 2013, 24:310-320.